Drug Trial Radar · NCT05163886
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Dec 23, 2021
Primary completion
Jan 11, 2023
Study completion May 31, 2025
Sponsor
- Lead sponsor
- IRulya Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).
Conditions
- Amyotrophic Lateral Sclerosis
- ALS
Interventions
LAM-002ADrug
LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.
PlaceboOther
Microcrystalline cellulose in Swedish orange, size 0 capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of LAM-002A: Occurrence of TEAEs and SAEsTime frame: 24 Weeks
- Tolerability of LAM-002A: Completion of Core Study TreatmentTime frame: 12 Weeks
- Plasma Pharmacokinetics of LAM-002A and Major MetabolitesTime frame: 24 Weeks
- CSF Pharmacokinetics of LAM-002A and Major MetabolitesTime frame: 24 Weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Johns Hopkins University School of Medicine
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.